WEGO Corporate and Strategy Overview
Business segment update
Medical
devices
Despite the impact of the pandemic on demand for medical devices, which further adversely
affected the sales volume of medical consumables, the Company leveraged the balanced
product portfolio, expanded customer base, and controlled to significantly increase the market
share
2022 % y-o-y
revenue
growth
Expanded the offerings in specialized fields such as anesthetic respiratory care, urology,
endocrinology, endoscopy, rehabilitation and digital products
Orthopedic
products
Seized the opportunity presented by VBP to become the leading provider in the market. With
hospitals listing WEGO as the top choice, the Company's market share is set to soar
Optimized the sales channels to streamline operation
✰ The impact of VBP has become milder, allowing us to quickly increasing market share and
promote innovation
Pharma
packaging
Interventional
products
✰ The pre-filled syringe injectors have achieved a y-o-y revenue growth of 9.3%. Excluding the
sales of the COVID vaccines, sales volume of the pre-filled syringe injectors has grown by 42%
✰ WEGO will enhance production capacity to capture the market demand, strengthen service
capabilities catering to downstream pharmaceutical companies, increase client loyalty to capture
the sustained long-term growth of the industry
Explore overseas opportunities to increase global market share
Excluding the impacts from supply chain challenge, Argon's revenue has achieved about 15% of
y-o-y growth
Argon's new product registration process and marketing efforts in China have progressed
smoothly, resulted in a 23.3% revenue growth from China market
% of segment¹
% of revenue
profit
+5.2%
50.4%
41.5%
-13.9%
13.4%
18.4%
+3.2%
15.5%
28.6%
+11.8%
12.7%
4.7%
+12.4%
8.0%
6.8%
Blood
management
WEGO威高
With the support from WEGO, Argon's global supply chain will gradually resume and is projected
to return to a growth rate of over 15%
As a leading player in the domestic blood collection industry, WEGO will leverage its expertise in
blood collection to expand its presence in areas such as blood component collection and blood
therapy, while actively pursuing opportunities to enter overseas markets
Rad Source has recorded a revenue y-o-y growth of 29%. The direct-to-consumer irradiators
have registered a sales of 80 units, and are used for irradiation of raw materials, particles and
seeds to eliminate pathogens and parasites. There is a significant potential for expanded
application use
Note: 1 The calculation of profit breakdown does not include other segment profits of RMB64.02mm.
4View entire presentation